|Day Low/High||8.40 / 8.62|
|52 Wk Low/High||7.80 / 18.00|
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the February 2018 expiration.
Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the July 2018 expiration.
The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 2,150,673 share decrease in total short interest for Lexicon Pharmaceuticals, Inc. , to 13,435,509, a decrease of 13.80% since 10/13/2017.
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the December 15th expiration.
First-in-Class Oral Tryptophan Hydroxylase Inhibitor that Sustains Improvement of Carcinoid Syndrome Diarrhea in Adults Inadequately Controlled by Somatostatin Analogs
The most recent short interest data was recently released for the 08/31/2017 settlement date, and Lexicon Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 31.32 "days to cover" versus the median component at 6.19.
InTandem3 Data Presented in Oral Symposium at EASD 2017
- Patients on sotagliflozin 200 mg spent 1.3 hours longer in target glucose range per day than placebo
A1C Benefit Sustained over 52 Weeks
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading today, for the September 15th expiration.
First -in-Class Oral Tryptophan Hydroxylase Inhibitor to be Considered for Approval in Europe for the Treatment of Carcinoid Syndrome Diarrhea in Combination with Somatostatin Analog Therapy
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.